|
|||||
|
|
Antifungal Susceptibility Profile of Candida Albicans Isolated from Vulvovaginal Candidiasis in Xinjiang Province of China |
|
| Authors: | Yan Liang Wang Xiao-dong Seyedmousavi Seyedmojtaba Yuan Juan-na Abulize Palida Pan Wei-hua Yu Nong Yang Ya-li Hu Hai-qing Liao Wan-qing Deng Shu-wen |
| Affiliation: | 1.The People’s Hospital of Suzhou National New & Hi-Tech Industrial Development Zone, Suzhou, Jiangsu, China ;2.Shanghai Key Laboratory of Medical Molecular Mycology & PLA Key Laboratory of Fungal Disease, Department of Dermatology, Changzheng Hospital, Second Military Medical University, Shanghai, China ;3.Wuhan General Hospital of Chinese PLA, Wuhan, Hubei, China ;4.The First Affiliated Hospital of Xinjiang Medical University, ürümqi, Xinjiang, China ;5.Molecular Microbiology Section, Laboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA ;6.Center of Expertise in Microbiology, Infection Biology and Antimicrobial Pharmacology, Tehran, Iran ;7.Invasive Fungi Research Center, School of Medicine, Mazandaran University of Medical Sciences, Sari, Iran ;8.The Second Affiliated Hospital of Guangzhou University of Chinese Medicine Guangdong Provincial Hospital of Chinese Medicine, Guangzhou, Guangdong, China ;9.Department of Laboratory Medicine, Changzheng Hospital, Second Military Medical University, Shanghai, China ; |
| Abstract: | We investigated the antifungal susceptibility profiles of 207 independent Candida albicans strains isolated from patients with vulvovaginal candidiasis (VVC) in Xinjiang Province of China. Using CLSI M27-A3 and M27-S4 guidelines, anidulafungin and micafungin were the most active drugs against C. albicans showing an MIC50/MIC90 corresponding to 0.016/0.0313 µg/mL, followed by caspofungin (0.25/0.25 µg/mL), posaconazole (0.125/0.5 µg/mL), ravuconazole (0.063/1 µg/mL), itraconazole (0.125/1 µg/mL), amphotericine B (0.5/1 µg/mL), isavuconazole (0.063/2 µg/mL), 5-flucytosine (1/2 µg/mL), voriconazole (0.125/4 µg/mL), and fluconazole (0.5/4 µg/mL). 96.1% (199)–100.0% (207) isolates were sensitive to the three echinocandins tested, amphotericine B and 5-flucytosine. The in vitro activity of triazoles against all isolates tested was variable; itraconazole and voriconazole had reduced the activity to almost half of the isolates (55.1% (114) and 51.2% (106) susceptible, respectively). Fluconazole was active against 76.3% (158) isolates tested. The new triazoles ravuconazole, isavuconazole and posaconazole showed good in vitro potency against 89.9% (186)–95.2% (197) of isolates with the geometric mean MIC (µg/mL) of 0.10, 0.12 and 0.14 µg/mL, respectively. In conclusion, our study indicates that for effective management of systemic candidiasis in Xinjiang Province of China, it is important to determine the susceptibility profiles of isolated C. albicans from patients with VVC. |
| Keywords: | |
| 本文献已被 SpringerLink 等数据库收录！ | |